Clinical Trial

Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 23, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a non-randomized, open-label, parallel, single-dose study to evaluate the pharmacokinetic profile of olverembatinib in participants with normal or impaired liver function.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-21
Trial Details
NCT Number NCT07282093
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: Guangzhou Healthquest Pharma Co., Ltd
Conditions Pharmacokinetic, Olverembatinib
Enrollment 48 participants
Start Date 2025-11-11
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-23